1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Rheumatoid	_	_	NN	_	_	_	_	_
2	arthritis	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	RA	_	_	NN	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	autoimmune	_	_	JJ	_	_	_	_	_
9	condition	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	characterized	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	symmetrical	_	_	JJ	_	_	_	_	_
14	joint	_	_	NN	_	_	_	_	_
15	inflammation	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	affects	_	_	VBZ	_	_	_	_	_
19	approximately	_	_	RB	_	_	_	_	_
20	1	_	_	CD	_	_	_	_	_
21	%	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	world	_	_	NN	_	_	_	_	_
25	’s	_	_	POS	_	_	_	_	_
26	population	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	RA	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	characterized	_	_	VBN	_	_	_	_	_
4	mainly	_	_	RB	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	synovium	_	_	NN	_	_	_	_	_
7	hyperplasia	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	joint	_	_	JJ	_	_	_	_	_
11	destruction	_	_	NN	_	_	_	_	_
12	process	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	scenario	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	immune	_	_	JJ	_	_	_	_	_
6	cells	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	inflammatory	_	_	JJ	_	_	_	_	_
10	microenvironment	_	_	NN	_	_	_	_	_
11	that	_	_	WDT	_	_	_	_	_
12	they	_	_	PRP	_	_	_	_	_
13	create	_	_	VBP	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	affected	_	_	VBN	_	_	_	_	_
16	joints	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	key	_	_	JJ	_	_	_	_	_
19	components	_	_	NNS	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	pathophysiology	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	RA	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	well-described	_	_	JJ	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	during	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	inflammatory	_	_	JJ	_	_	_	_	_
10	stages	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	disease	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	extra-articular	_	_	JJ	_	_	_	_	_
16	manifestations	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	common	_	_	JJ	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	involve	_	_	VBP	_	_	_	_	_
22	other	_	_	JJ	_	_	_	_	_
23	tissues	_	_	NNS	_	_	_	_	_
24	or	_	_	CC	_	_	_	_	_
25	organs	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	RA	_	_	NNP	_	_	_	_	_
2	patients	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	at	_	_	IN	_	_	_	_	_
5	risk	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	systemic	_	_	JJ	_	_	_	_	_
8	complications	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	several	_	_	JJ	_	_	_	_	_
11	co-morbidities	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	osteoporosis	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	frequent	_	_	JJ	_	_	_	_	_
17	vertebral	_	_	JJ	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	hip	_	_	NN	_	_	_	_	_
20	fragility	_	_	NN	_	_	_	_	_
21	fractures	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	incidence	_	_	NN	_	_	_	_	_
3	rate	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	overall	_	_	JJ	_	_	_	_	_
6	fractures	_	_	NNS	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	RA	_	_	NNP	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	33	_	_	CD	_	_	_	_	_
12	per	_	_	IN	_	_	_	_	_
13	1000	_	_	CD	_	_	_	_	_
14	person-years	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	risk	_	_	NN	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	increased	_	_	VBN	_	_	_	_	_
21	with	_	_	IN	_	_	_	_	_
22	disease	_	_	NN	_	_	_	_	_
23	activity	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	associated	_	_	VBN	_	_	_	_	_
26	with	_	_	IN	_	_	_	_	_
27	overexpression	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	pro-inflammatory	_	_	JJ	_	_	_	_	_
30	cytokines	_	_	NNS	_	_	_	_	_
31	that	_	_	WDT	_	_	_	_	_
32	can	_	_	MD	_	_	_	_	_
33	disturb	_	_	VB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	bone	_	_	NN	_	_	_	_	_
36	remodeling	_	_	NN	_	_	_	_	_
37	process	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Over	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	last	_	_	JJ	_	_	_	_	_
4	decades	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	animal	_	_	NN	_	_	_	_	_
7	models	_	_	NNS	_	_	_	_	_
8	—	_	_	:	_	_	_	_	_
9	especially	_	_	RB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	rodent	_	_	NN	_	_	_	_	_
12	models	_	_	NNS	_	_	_	_	_
13	—	_	_	:	_	_	_	_	_
14	have	_	_	VBP	_	_	_	_	_
15	been	_	_	VBN	_	_	_	_	_
16	crucial	_	_	JJ	_	_	_	_	_
17	tools	_	_	NNS	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	understanding	_	_	VBG	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	biologic	_	_	JJ	_	_	_	_	_
22	process	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	RA	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	their	_	_	PRP$	_	_	_	_	_
28	use	_	_	NN	_	_	_	_	_
29	can	_	_	MD	_	_	_	_	_
30	aid	_	_	VB	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	developing	_	_	VBG	_	_	_	_	_
33	new	_	_	JJ	_	_	_	_	_
34	therapeutic	_	_	JJ	_	_	_	_	_
35	strategies	_	_	NNS	_	_	_	_	_
36	for	_	_	IN	_	_	_	_	_
37	fracture	_	_	NN	_	_	_	_	_
38	healing	_	_	NN	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	RA	_	_	NN	_	_	_	_	_
41	inflammatory	_	_	JJ	_	_	_	_	_
42	conditions	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	Collagen	_	_	NNP	_	_	_	_	_
2	induced-arthritis	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	CIA	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_
6	animal	_	_	NN	_	_	_	_	_
7	models	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	been	_	_	VBN	_	_	_	_	_
10	one	_	_	CD	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	most	_	_	RBS	_	_	_	_	_
14	widely	_	_	RB	_	_	_	_	_
15	used	_	_	VBN	_	_	_	_	_
16	models	_	_	NNS	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	RA	_	_	NNP	_	_	_	_	_
19	research	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Originally	_	_	RB	_	_	_	_	_
2	described	_	_	VBN	_	_	_	_	_
3	by	_	_	IN	_	_	_	_	_
4	Trentham	_	_	NNP	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	CIA	_	_	NNP	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	reproducible	_	_	JJ	_	_	_	_	_
10	animal	_	_	JJ	_	_	_	_	_
11	experimental	_	_	JJ	_	_	_	_	_
12	model	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	RA	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	fact	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	similarity	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	human	_	_	JJ	_	_	_	_	_
8	RA	_	_	NN	_	_	_	_	_
9	regarding	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	disease	_	_	NN	_	_	_	_	_
12	clinical	_	_	JJ	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	histological	_	_	JJ	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	immunological	_	_	JJ	_	_	_	_	_
18	signals	_	_	NNS	_	_	_	_	_
19	—	_	_	:	_	_	_	_	_
20	including	_	_	VBG	_	_	_	_	_
21	high	_	_	JJ	_	_	_	_	_
22	articular	_	_	JJ	_	_	_	_	_
23	levels	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	inflammatory	_	_	JJ	_	_	_	_	_
26	cytokines	_	_	NNS	_	_	_	_	_
27	—	_	_	:	_	_	_	_	_
28	like	_	_	IN	_	_	_	_	_
29	tumor	_	_	NN	_	_	_	_	_
30	necrosis	_	_	NN	_	_	_	_	_
31	factor-α	_	_	NN	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	TNF-α	_	_	NN	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	make	_	_	VB	_	_	_	_	_
37	it	_	_	PRP	_	_	_	_	_
38	an	_	_	DT	_	_	_	_	_
39	invaluable	_	_	JJ	_	_	_	_	_
40	model	_	_	NN	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	study	_	_	VB	_	_	_	_	_
43	the	_	_	DT	_	_	_	_	_
44	pathologic	_	_	JJ	_	_	_	_	_
45	process	_	_	NN	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	to	_	_	TO	_	_	_	_	_
48	search	_	_	VB	_	_	_	_	_
49	new	_	_	JJ	_	_	_	_	_
50	therapeutic	_	_	JJ	_	_	_	_	_
51	strategies	_	_	NNS	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	response	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	rat	_	_	NN	_	_	_	_	_
5	CIA	_	_	NNP	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	reported	_	_	VBN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	involve	_	_	VB	_	_	_	_	_
11	macrophages	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	T	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	B	_	_	NN	_	_	_	_	_
16	lymphocytes	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	mediators	_	_	NNS	_	_	_	_	_
20	such	_	_	JJ	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	TNF-α	_	_	NNP	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	Interleukin	_	_	NNP	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	IL)-1β	_	_	NNP	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	IL-6	_	_	NNP	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	IL-17	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Nonetheless	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	systemic	_	_	JJ	_	_	_	_	_
5	response	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	this	_	_	DT	_	_	_	_	_
8	model	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	well	_	_	RB	_	_	_	_	_
13	characterized	_	_	VBN	_	_	_	_	_
14	so	_	_	RB	_	_	_	_	_
15	far	_	_	RB	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Importantly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	current	_	_	JJ	_	_	_	_	_
4	RA	_	_	NN	_	_	_	_	_
5	treatments	_	_	NNS	_	_	_	_	_
6	do	_	_	VBP	_	_	_	_	_
7	not	_	_	RB	_	_	_	_	_
8	promote	_	_	VB	_	_	_	_	_
9	joint	_	_	JJ	_	_	_	_	_
10	repair	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	several	_	_	JJ	_	_	_	_	_
14	efforts	_	_	NNS	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	being	_	_	VBG	_	_	_	_	_
17	made	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	develop	_	_	VB	_	_	_	_	_
20	new	_	_	JJ	_	_	_	_	_
21	therapies	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	especially	_	_	RB	_	_	_	_	_
24	based	_	_	VBN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	cell	_	_	NN	_	_	_	_	_
27	approaches	_	_	NNS	_	_	_	_	_
28	using	_	_	VBG	_	_	_	_	_
29	mesenchymal	_	_	JJ	_	_	_	_	_
30	stem/stromal	_	_	NN	_	_	_	_	_
31	cells	_	_	NNS	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	MSC	_	_	NNP	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	MSC	_	_	NNP	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	multipotent	_	_	JJ	_	_	_	_	_
4	progenitor	_	_	NN	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	potential	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	differentiate	_	_	VB	_	_	_	_	_
11	into	_	_	IN	_	_	_	_	_
12	mesenchymal	_	_	JJ	_	_	_	_	_
13	lineage	_	_	NN	_	_	_	_	_
14	tissues	_	_	NNS	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	e.	_	_	FW	_	_	_	_	_
17	g.	_	_	FW	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	bone	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	cartilage	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	adipose	_	_	NN	_	_	_	_	_
25	tissue	_	_	NN	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	described	_	_	VBN	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	have	_	_	VB	_	_	_	_	_
31	immunomodulatory	_	_	JJ	_	_	_	_	_
32	roles	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	being	_	_	VBG	_	_	_	_	_
35	capable	_	_	JJ	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	recruiting	_	_	VBG	_	_	_	_	_
38	different	_	_	JJ	_	_	_	_	_
39	cell	_	_	NN	_	_	_	_	_
40	types	_	_	NNS	_	_	_	_	_
41	and	_	_	CC	_	_	_	_	_
42	promoting	_	_	VBG	_	_	_	_	_
43	tissue	_	_	NN	_	_	_	_	_
44	repair	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	transplantation	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	MSC	_	_	NNP	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	reported	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	ameliorate	_	_	VB	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	delay	_	_	VB	_	_	_	_	_
12	RA	_	_	NN	_	_	_	_	_
13	onset	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	CIA	_	_	NNP	_	_	_	_	_
16	animals	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	partially	_	_	RB	_	_	_	_	_
19	mediated	_	_	VBN	_	_	_	_	_
20	by	_	_	IN	_	_	_	_	_
21	inflammatory	_	_	JJ	_	_	_	_	_
22	signaling	_	_	NN	_	_	_	_	_
23	suppression	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	thereby	_	_	RB	_	_	_	_	_
27	reducing	_	_	VBG	_	_	_	_	_
28	joint	_	_	JJ	_	_	_	_	_
29	swelling	_	_	NN	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	destruction	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	available	_	_	JJ	_	_	_	_	_
4	evidence	_	_	NN	_	_	_	_	_
5	supports	_	_	VBZ	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	use	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	MSC	_	_	NNP	_	_	_	_	_
10	transplantation	_	_	NN	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	cell-based	_	_	JJ	_	_	_	_	_
14	strategy	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	CIA	_	_	NNP	_	_	_	_	_
17	animals	_	_	NNS	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	data	_	_	NNS	_	_	_	_	_
20	on	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	biology	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	endogenous	_	_	JJ	_	_	_	_	_
25	CIA	_	_	NNP	_	_	_	_	_
26	animals-derived	_	_	JJ	_	_	_	_	_
27	MSC	_	_	NN	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	basal	_	_	JJ	_	_	_	_	_
30	conditions	_	_	NNS	_	_	_	_	_
31	is	_	_	VBZ	_	_	_	_	_
32	scarce	_	_	JJ	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	impact	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	systemic	_	_	JJ	_	_	_	_	_
8	inflammatory	_	_	JJ	_	_	_	_	_
9	condition	_	_	NN	_	_	_	_	_
10	on	_	_	IN	_	_	_	_	_
11	biological	_	_	JJ	_	_	_	_	_
12	properties	_	_	NNS	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	endogenous	_	_	JJ	_	_	_	_	_
15	MSC	_	_	NNP	_	_	_	_	_
16	has	_	_	VBZ	_	_	_	_	_
17	not	_	_	RB	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	explored	_	_	VBN	_	_	_	_	_
20	yet	_	_	RB	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Herein	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	propose	_	_	VBP	_	_	_	_	_
5	CIA	_	_	NNP	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	reliable	_	_	JJ	_	_	_	_	_
9	model	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	study	_	_	VB	_	_	_	_	_
12	bone	_	_	NN	_	_	_	_	_
13	regeneration	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	inflammatory	_	_	JJ	_	_	_	_	_
16	conditions	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	additionally	_	_	RB	_	_	_	_	_
20	we	_	_	PRP	_	_	_	_	_
21	investigate	_	_	VBP	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	effect	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	RA	_	_	NN	_	_	_	_	_
26	induction	_	_	NN	_	_	_	_	_
27	on	_	_	IN	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	biological	_	_	JJ	_	_	_	_	_
30	behavior	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	endogenous	_	_	JJ	_	_	_	_	_
33	MSC	_	_	NN	_	_	_	_	_
34	as	_	_	IN	_	_	_	_	_
35	crucial	_	_	JJ	_	_	_	_	_
36	cells	_	_	NNS	_	_	_	_	_
37	involved	_	_	VBN	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	repair/regeneration	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	combination	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	two	_	_	CD	_	_	_	_	_
11	models	_	_	NNS	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	feasible	_	_	JJ	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	that	_	_	IN	_	_	_	_	_
16	CIA	_	_	NNP	_	_	_	_	_
17	animals	_	_	NNS	_	_	_	_	_
18	respond	_	_	VBP	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	bone	_	_	NN	_	_	_	_	_
22	injury	_	_	NN	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	a	_	_	DT	_	_	_	_	_
25	significant	_	_	JJ	_	_	_	_	_
26	increase	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	systemic	_	_	JJ	_	_	_	_	_
29	myeloid	_	_	NN	_	_	_	_	_
30	cells	_	_	NNS	_	_	_	_	_
31	number	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	their	_	_	PRP$	_	_	_	_	_
34	co-stimulatory	_	_	JJ	_	_	_	_	_
35	molecules	_	_	NNS	_	_	_	_	_
36	(	_	_	-LRB-	_	_	_	_	_
37	CD40	_	_	NN	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	CD86	_	_	NN	_	_	_	_	_
40	)	_	_	-RRB-	_	_	_	_	_
41	expression	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	accompanied	_	_	VBN	_	_	_	_	_
44	by	_	_	IN	_	_	_	_	_
45	increased	_	_	VBN	_	_	_	_	_
46	levels	_	_	NNS	_	_	_	_	_
47	of	_	_	IN	_	_	_	_	_
48	IL-13	_	_	NNP	_	_	_	_	_
49	,	_	_	,	_	_	_	_	_
50	IL-2	_	_	NNP	_	_	_	_	_
51	,	_	_	,	_	_	_	_	_
52	and	_	_	CC	_	_	_	_	_
53	IL-6	_	_	NNP	_	_	_	_	_
54	in	_	_	IN	_	_	_	_	_
55	plasma	_	_	NN	_	_	_	_	_
56	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	systemic	_	_	JJ	_	_	_	_	_
3	inflammatory	_	_	JJ	_	_	_	_	_
4	environment	_	_	NN	_	_	_	_	_
5	created	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	arthritis	_	_	NN	_	_	_	_	_
9	induction	_	_	NN	_	_	_	_	_
10	leads	_	_	VBZ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	decreased	_	_	VBN	_	_	_	_	_
13	metabolic	_	_	JJ	_	_	_	_	_
14	activity	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	proliferation	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	CIA-derived	_	_	JJ	_	_	_	_	_
19	MSC	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	increased	_	_	VBD	_	_	_	_	_
23	differentiation	_	_	NN	_	_	_	_	_
24	capacity	_	_	NN	_	_	_	_	_
25	determined	_	_	VBN	_	_	_	_	_
26	by	_	_	IN	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	expression	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	osteogenic	_	_	JJ	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	runt-related	_	_	JJ	_	_	_	_	_
33	transcription	_	_	NN	_	_	_	_	_
34	factor	_	_	NN	_	_	_	_	_
35	2	_	_	CD	_	_	_	_	_
36	(	_	_	-LRB-	_	_	_	_	_
37	RUNX2	_	_	NN	_	_	_	_	_
38	)	_	_	-RRB-	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	alkaline	_	_	JJ	_	_	_	_	_
41	phosphatase	_	_	NN	_	_	_	_	_
42	(	_	_	-LRB-	_	_	_	_	_
43	ALP	_	_	NN	_	_	_	_	_
44	)	_	_	-RRB-	_	_	_	_	_
45	)	_	_	-RRB-	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	chondrogenic	_	_	JJ	_	_	_	_	_
49	(	_	_	-LRB-	_	_	_	_	_
50	aggrecan	_	_	NN	_	_	_	_	_
51	(	_	_	-LRB-	_	_	_	_	_
52	ACAN	_	_	NN	_	_	_	_	_
53	)	_	_	-RRB-	_	_	_	_	_
54	)	_	_	-RRB-	_	_	_	_	_
55	markers	_	_	NNS	_	_	_	_	_
56	in	_	_	IN	_	_	_	_	_
57	basal	_	_	JJ	_	_	_	_	_
58	conditions	_	_	NNS	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_

